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Background: To evaluate the outcome of breast cancer patients after locoregional recurrence (LRR) according to
tumor biological features evaluated at first diagnosis and at the time of recurrence.
Patients and methods: We collected information on all consecutive breast cancer patients operated at the
European Institute of Oncology between 1994 and 2005. The tumor characteristics and subsequent outcome of
patients who experienced LRR were analyzed.
Results: Two hundred and seventy nine patients with LRR were identified, 197 and 82 patients with local and
regional recurrence respectively. The overall discordance rate between primary cancer and LRR was 9% for
estrogen receptor expression, 22% for progesterone receptor and 4% for human epidermal growth factor
receptor 2. For patients with regional recurrence, the risk of distant metastasis was significantly higher compared
with local relapse in case of late recurrence (hazard ratio [HR] = 2.76; 95% CI 1.31–5.85). Patients with triple-
negative breast cancer at LRR experienced a higher risk of subsequent relapse (HR 2.87 [1.67–4.91]) and death
(HR 2.00 [1.25–3.19]).
Conclusion: LRR correlates with a high risk of subsequent events and death in particular in patients with
triple-negative subtype.
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introduction
Locoregional recurrences (LRR) may occur in a significant
proportion of patients after primary therapy despite careful
local treatment and systemic adjuvant therapies and or
radiotherapy [1–3]. Patients who are free of overt metastases
after initial local and regional treatment eventually die of
recurrence of distant disease. In particular, breast cancer
patients with LRR have been found to have 5-year disease-free
survival (DFS) rates of 13%–37% and overall survival (OS)
rates of 21%–50% [4–6], respectively.
A 10-year estimated OS rate of up to 26% has been reported,
indicating that long-term reappearance of disease should be
taken into account [5, 7]. Moreover, the outcome is worse after
regional recurrence compared with local [8].
A better description of relapse patterns may improve patient
outcome by permitting a better understanding of patients’
subgroup-specific risk, which could lead to targeted therapeutic
approaches. Recently, different subtypes of breast cancer have
been identified based on gene expression profiles and
immunohistochemical evaluations with specific responsiveness
to treatments and outcome [9–11]. In particular, Hugh et al.
[12] reported that patients with ER (estrogen receptor)-
negative tumors (both triple negative and HER2 [human
epidermal growth factor receptor 2] positive) showed a better
response to adjuvant taxane-containing chemotherapy than
to chemotherapy that does not contain taxane. Moreover, the
magnitude of the effect for the classical combination
chemotherapy with cyclophosphamide, methotrexate and
fluorouracil regimen was reported to be larger in patients with
the triple-negative subtype [13].
Given, the paramount importance of using targeted therapies
wherever possible for adjuvant treatment, timely, accurate
and reliable histopathologic assessment that identifies and
quantifies the target is essential. We therefore aimed to evaluate
the influence of LRR on disease outcome in a large series of
patients who were homogeneously diagnosed and treated in
a single institution according to tumor biological features
evaluated at first diagnosis and at the time of recurrence.
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patients and methods
patients
We reviewed information on 14 733 consecutive breast cancer patients
whose definitive breast cancer surgery was carried out at the European
Institute of Oncology between 1994 and 2005. Data on the patient’s medical
history, concurrent diseases, surgery, pathological evaluation, and results of
staging procedures (blood chemistry, hematologic values, bone scan, chest
film and upper abdominal ultrasound examination) were required. This
report concerns patients who subsequently developed LRR as first event.
We excluded patients who initially presented with bilateral breast tumor
or who received neoadjuvant treatments. Following surgery, all cases were
discussed during the weekly multidisciplinary meeting attended by
surgeons, medical oncologists, radiation oncologists and pathologists.
The decision for adjuvant systemic treatment was made on the basis of
biological features, staging, treatment previously received and
comorbidities. Women were usually followed up by physical examination
every 6 months and mammography with or without breast ultrasound
(US) annually. In symptomatic cases or when clinically indicated, bone
scan, chest X-ray, liver US or computed tomography scan were carried out.
We identified patients who experienced LRR as first event without evidence
of distant metastasis. A recurrence was categorized as local (in the ipsilateral
breast in case of primary breast-conserving treatment, operation scar, or chest
wall or skin) or regional (in the axillary lymph nodes or the supraclavicular
region internal mammary or supraclavicular or infraclavicular nodes).
Patients with LRR were treated according to standard multidisciplinary
protocols. All patients received adequate local treatment using surgery,
radiotherapy or both. The selection of systemic treatment was individually
based upon indicators of responsiveness to treatment (ER, PgR
[progesterone receptor] and HER2 expression of the tumor), previous
treatment and indicators of risk. According to the recent classification of
breast cancer, we identified four immunohistochemically defined tumor
subtypes: triple negative (ER, PgR and HER2 negative), HER2 positive
(HER2 positive, ER and PgR negative) and endocrine-responsive: luminal
A (with ER and/or PgR > 1%, Ki-67 < 14% and HER2 negative) and
luminal B (with ER and/or PgR > 1%and Ki-67 ‡ 14% or HER2 positive or
both). Patients with the luminal A subtype were commonly candidate to
endocrine therapies selected upon previous endocrine agents received.
Patients with the luminal B subtype also received short-term (four courses)
chemotherapy (e.g. anthracyclines- or taxanes-containing chemotherapy),
whereas those with triple-negative breast cancer were candidate to cisplatin-
containing chemotherapy or alkylating-containing chemotherapy for 4–6
months. In case of HER2 overexpression and/or amplification, trastuzumab
for 12 months was prescribed starting from 2005.
pathology and immunohistochemistry
In this single institution study, all patients had pathological evaluation
carried out in the European Institute of Oncology both at primary surgery
and at LRR.
Immunostaining for the localization of ER and PgR, HER2 protein and
Ki-67 antigen was carried out on consecutive tissue sections from the
tumor-containing blocks, as previously reported [14]. The following
primary antibodies were used: the monoclonal antibody (MAb) to ER
(Dako, Glostrup, Denmark at 1/100 dilution), the MAb to PgR (Dako at
1/800 dilution), the MIB-1 MAb to the Ki-67 antigen (Immunotech,
Marseille, France, 1/1200) and the polyclonal antiserum (Dako at 1/3200
dilution) to the HER2 protein.
Only nuclear reactivity was taken into account for ER, PgR and Ki-67
antigen, whereas only an intense and complete membrane staining in >10%
of the tumor cells qualified for HER2 overexpression (3+). The results
for ER, PgR and Ki-67 were recorded as the percentage of immunoreactive
cells observed among at least 2000 neoplastic cells. The value Ki-67 labeling
index was divided into low (<14%) and high (‡14%) [11].
statistical analysis
The Pearson v2 test was used to compare the distribution of clinical and
pathological variables between patients with local and regional recurrence
as first event.
The end points evaluated were progression-free survival (PFS), OS,
cumulative incidence of LRR (CI-LR) and distant recurrence (CI-D),
all measured from the date of LRR.
PFS was defined as the length of time from the date of LRR to any
subsequent relapse (including ipsilateral breast recurrence, contralateral
breast cancer, appearance of a second primary cancer) or death, whichever
occurred first.
OS was defined as the time from the date of LRR until the date of death
(from any cause).
The PFS and OS functions were estimated using the Kaplan–Meier
method. The log-rank test was used to assess differences between patients
with local versus regional recurrence as first event.
The CI-LR and CI-D were defined as the length of time from the date of
first LRR to a second LRR and distant metastases, respectively.
The CI-LR and CI-D curves functions were estimated according to methods
described by Kalbfleisch and Prentice [15], taking into account the competing
causes of recurrence. The Gray’s test was used to assess cumulative incidence
differences between patients with local and regional recurrence as first event [16].
The prognostic impact of several factors on PFS, OS and cause-specific
hazard was evaluated using multivariable Cox proportional hazards
regression models and expressed as hazard ratio (HR) with 95% confidence
interval (CI) [17]. All analyses were carried out with the SAS software (SAS
Institute, Cary, NC) and the R software (http://cran.r-project.org/) with the
cmprsk package developed by Gray (http://biowww.dfci.harvard.edu/
gray). All reported P-values are two-sided.
results
A total of 14 733 consecutive patients with breast cancer who
had definitive surgery for breast cancer, referred for
interdisciplinary evaluation between 1994 and 2005 and
included in a prospective quality-controlled database, were
analyzed. We excluded patients who presented with metastatic
disease (n = 364), other previous primary tumor (n = 400),
previous contralateral breast cancer (n = 420), recurrent disease
at presentation (n = 683), primary chemotherapy (n = 1341)
and male breast cancer (n = 73). On the remaining 11 452
patients, a total of 279 patients with LRR (197 and 82 patients
with local and regional recurrence) were identified.
At the time of the primary cancer of study population,
74% and 58% of patients with subsequent local and regional
recurrence respectively had undergone conservative surgery.
Regional recurrence occurred more frequently than local
recurrence (31% versus 26%) among patients who presented
with four or more positive lymph nodes at primary surgery.
After primary surgery, 12% of study patients didn’t receive
any adjuvant therapy, 63% received endocrine therapy, 61%
chemotherapy (36% received both), while adjuvant standard
radiotherapy or intraoperative electron beam (ELIOT)
radiotherapy was used in 62% of cases. Only one patient
received trastuzumab in the adjuvant setting.
Annals of Oncology original articles








ilan user on 05 April 2019
Table 1 reports the timing and clinical and biological features
at LRR and treatment received. Twelve percent and 16% of
patients with local and regional recurrence had a time to LRR
<1 year. The time to LRR from primary breast cancer was from
2 to 4 years in the 32% of the local recurrence group and in the
38% of regional recurrence group. The median time to LRR
was 2.6 years (range 0.3–9.3 years). Only 12% and 8% in the
local and regional group respectively did not receive an
adjuvant systemic therapy.
Table 2 shows the comparison of biological features and
subtypes between primary cancer and LRR. We reported an
overall discordance rate of 9% for ER expression, 22% for
PgR expression, 19% for Ki-67, 4% for HER2 and 22% for
subtypes. For the hormonal receptor status, more frequently
we reported a loss of expression in the LRR compared with
primary tumor. In particular, 18 breast cancer cases with ER
positive became negative at LRR, while 46 tumors with PgR
positive became negative at relapse.
Median follow up after LRR was 5.9 years (range 0.9–12.2
years). The Kaplan–Meier curves for PFS and OS according to the
type of relapse (local or regional) are displayed in Figure 1A and
B. The 5-year PFS and OS were 45% and 71% in the local
recurrence group compared wirh 34% and 58% in the regional
recurrence group (P = 0.052 for PFS and P = 0.063 for OS). Figure
1C and D shows the CI-LR alone and CI-D. The 5-year CI-LR
and CI-D were 25% and 21% in the local recurrence
group compared with 5-year CI-LR and CI-D of 21%
and 36% in the regional recurrence group. (P = 0.39 for CI-LR
and P = 0.013 for CI-D).
Moreover, we evaluated the impact of early recurrence
(<2 years) on CI-D in both local and regional groups. For
patients with local recurrence, the CI-D was significantly higher
in case of early recurrence compared with late relapse; in the
meanwhile, patients with regional recurrence continue to have
higher risk of distant metastasis despite to time of recurrence
(interaction P-value = 0.003) (Figure 2A and B).
The Kaplan–Meier curves for PFS and OS according to the
subtypes at recurrence are shown in Figure 3. We reported the
highest incidence of subsequent event among those patients
presenting with the triple-negative subtype. In particular, after
2 years the PFS was 36% (95% CI 22% to 51%) and OS 60%
(95% CI 46% to 74%).
At the time of the study analyses, 103 patients were free of
disease, 73 patients experienced new LRR and 74 patients
experienced distant recurrence with bone involvement in 36
patients. The 5-year CI of bone involvement was 8% in patients
with local recurrence and 19% in patients with regional
recurrence (P = 0.04).
Moreover, for patients with local recurrence, we evaluated
the outcome according to the type of surgery (quadrantectomy
or mastectomy) at primary cancer. No differences were
observed.
multivariate analysis
The independent impact on time to event following LRR was
assessed for various features of the primary cancer and type
of LRR. The results are displayed in Table 3.
For patients with regional recurrence, the risk of distant
metastasis was significantly higher compared with local relapse
in case of late recurrence (HR 2.76; 95% CI 1.31–5.85).
The presence of vascular invasion (HR 1.59; 95% CI
0.96–2.65 for PFS, HR 1.61; 95% CI 1.09–2.37 for OS) and high
grade at primary cancer (HR 1.76; 95% CI 1.06–2.94 for PFS,
HR 1.40; 95% CI 0.95–2.08 for OS) were associated with worse
PFS and OS. Triple-negative breast cancer subtype at
Table 1. Characteristics at first locoregional recurrence and treatment





n (%) n (%) Pa
Year of recurrence 0.40
<2001 32 (16.2) 12 (14.6)
2001–2003 65 (33.0) 34 (41.5)
2004–2005 100 (50.8) 36 (43.9)
Age (years) 0.34
<35 10 (5.1) 2 (2.4)
35–50 78 (39.6) 29 (35.4)
51–65 67 (34.0) 26 (31.7)
>65 42 (21.3) 25 (30.5)
Time to recurrence (years) 0.051
<1 24 (12.2) 13 (15.9)
1–2 46 (23.4) 25 (30.5)
2–4 64 (32.5) 31 (37.8)
>4 63 (32.0) 13 (15.9)
Breast cancer subtype b,c 0.81
Luminal A 30 (15.2) 8 (9.8)
Luminal Bd 99 (50.3) 44 (53.7)
HER2 positivee 26 (13.2) 12 (14.6)
Triple negative 32 (16.2) 13 (15.9)
Unknown 10 (5.1) 5 (6.1)
CT/HT 0.020
Nil 25 (12.6) 7 (8.5)
HT 101 (51.2) 33 (40.2)
CT 53 (26.9) 24 (29.2)
CT-HT 18 (9.1) 18 (21.9)
aChi-square test comparing frequencies between local recurrence group and
regional recurrence group.
bLuminal A: (ER > 0 or PgR > 0) and (Ki-67 < 14%) and (HER2 negative);
Luminal B: (ER > 0 or PgR > 0) and ([Ki-67 ‡ 14%] or [HER2 positive]);
HER2 positive: (ER = 0 and PgR = 0) and (HER2 positive); Triple negative
(ER negative and PgR negative) and (HER2 negative).
cIf any biological variable was unknown at locoregional recurrence, the
value at primary breast cancer was used. The value of Ki-67 expression was
unknown at locoregional recurrence in 12 luminal A, 48 luminal B, 9
HER2-positive and 15 triple-negative breast cancer subtypes. The HER2
status was unknown at locoregional recurrence in one HER2-positive and
two triple-negative breast cancer subtypes.
dAmong luminal B, 34 patients were HER2 positive (22 and 12 in local and
regional recurrence group, respectively). Among these, eight patients
received trastuzumab after recurrence (three and five in the local and
regional recurrence group, respectively).
eTwenty one patients received trastuzumab after recurrence (13 and 8 in the
local and regional recurrence group, respectively).
CT, chemotherapy; ER, estrogen receptor; HER2, human epidermal growth
factor receptor 2; HT, hormonal therapy; PgR, progesterone receptor.
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recurrence was associated with increased risk of subsequent
event and death (HR 2.87; 95% CI 1.67–4.91 for PFS, HR 2.00;
95% CI 1.25–3.19 for OS).
discussion
In this study, we evaluated the patterns of subsequent
recurrence among the 279 patients who had a first LRR. Our
focus was on subgroups of patients with higher risk of further
with the possibility of investigating targeted treatments. All the
patients included in the present analysis had a histological
evaluation both at first diagnosis and at recurrence at the same
institution. Thus, the evaluation of biological features carried
out by the same group of pathologist in all patients is a major
strength of the current analysis.
Our study confirms the negative prognostic impact of LRR in
breast cancer patients. The 5-year PFS and OS were 45% and
71% in the local recurrence group and 34% and 58% in the
regional recurrence group. Wapnir et al. [8] reported that
after local recurrence the proportion of patients who were free
of distant disease at 5 years was 51% and the proportion of
patients surviving was 60%. The 5-year distant DFS and OS
were 19% and 24% in patients who experienced regional
recurrence.
The most relevant observation concerning the patterns of
relapse was the highest incidence of subsequent event among
those patients presenting with the triple-negative subtype
(Figure 3). In fact at the multivariate analyses, we reported that
the triple-negative subtype at recurrence was significantly
associated with worse prognosis in terms of PFS and OS.
Moreover, patients with triple-negative tumors had a higher
early incidence of event. In particular, after 2 years the PFS was
36% (95% CI 22% to 51%) and OS, 60% (46% to 74%). It
is noteworthy that among the 45 patients with triple-negative
subtype, 33 (73%) of the patients received adjuvant
chemotherapy and 29 (64%) adjuvant radiotherapy.
Table 2. Qualitative changes in receptor expression (ER and PgR), Ki-67 and HER2 status between primary breast cancer and locoregional recurrence. For
ER and PgR, positive status was defined as ‡1%, high Ki-67 was defined as ‡14%, HER2-positive status was defined as >3
Locoregional recurrence Total
ER
Primary tumor Negative (n) Positive (n)
Negative 70 7 77
Positive 18 184 202
Total 88 191 279
Overall discordance rate (95% CI): 9.0% (5.9% to 12.9%)
PgR
Primary tumor Negative (n) Positive (n)
Negative 105 16 121
Positive 46 112 158
Total 151 128 279
Overall discordance rate (95% CI): 22.2% (17.5% to 27.6%)
HER2 statusa
Primary tumor Negative (n) Positive (n)
Negative 119 4 123
Positive 3 48 51
Total 122 52 174
Overall discordance rate (95% CI): 4.0% (1.6% to 8.1%)
Ki-67b
Primary tumor Low (n) High (n)
Low 12 13 25
High 21 135 156
Total 33 148 181
Overall discordance rate (95% CI): 18.8% (13.4% to 25.2%)
Breast cancer subtypec
Primary tumor Luminal A (n) Luminal B (n) HER2 positive (n) Triple negative (n)
Luminal A 7 5 0 1 13
Luminal B 8 48 4 9 69
HER2 positive 0 1 26 1 28
Triple negative 0 0 1 25 26
Total 15 54 31 36 136
Overall discordance rate (95% CI): 22.1% (15.4% to 30.0%)
aOne hundred and five patients with missing value at primary breast cancer or at locoregional recurrence were not considered.
bNinety eight patients with missing value at primary breast cancer or at locoregional recurrence were not considered.
cOne hundred and forty eight patients with missing value at primary breast cancer or at locoregional recurrence were not considered.
CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.
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We also compared pathological features of primary tumor
and LRR and we observed that the expression of biological
parameters changed between primary and recurrence (Table 2).
We reported an overall discordance rate of 9% for ER
expression, 22% for PgR expression (predominantly changed
from positive to negative) 19% for Ki-67 (mainly increased)
and 4% for HER2. In particular, 18 breast cancers with ER
positive became negative at LRR, while 46 tumors with PgR
positive became negative at relapse. Due to the low number
of cases, it is however difficult to investigate the predictive
or prognostic value of a changed receptor status. The
mechanisms of change of hormone receptor and HER2
expression have not been explicitly studied. Adjuvant
chemotherapy and hormonal therapy may eliminate specific
subclones of tumor cells, selecting others that dominate in the
recurrent disease [18]. Receptor status may also depend on
the analytical method used and by variation in tissue processing
and fixation.
Lower et al. [19] analyzed the concordance on HER2 status
between primary cancer and metastasis in 382 breast cancer
patients. The authors reported a higher rate of discordance in
33.2% of cases with 23.6% changed from positive to negative,
while 9.6% changed from negative to positive [19]. Other
studies have reported hormone receptor status discordance
rates of 21%–28% (predominantly loss of hormonal receptors)
between primary and breast relapse [20, 21]. In the studies
above mentioned, most comparisons regarded primary with
distant metastatic sites and very few patients with LRR were
included. In the study of Carreno et al. [22], the comparison
of primary tumor and LRR was done in 25 patients reporting
a substantial concordance in the expression of hormonal
receptor between primary tumor and LRR.
In our study, patients who experienced regional recurrence
had a worse prognosis than those with local relapse. Patients
with regional recurrence continue to have higher risk of distant
metastasis irrespective of time of relapse. Conversely, in
Figure 1. Progression-free survival (A), overall survival (B), cumulative incidence of locoregional event (C) and distant event (D) after first locoregional
recurrence, by type of first recurrence.
original articles Annals of Oncology








ilan user on 05 April 2019
patients with local recurrence a dismal prognosis was observed
only among those that experienced an early relapse. Other
studies also reported better a good outcome for patients with
late recurrence [23]. In case of local recurrence in fact, the late
relapse could suggest a second primary breast cancer more than
a relapse of the previous tumor.
Regarding the patterns of distant metastases, we reported
a high incidence of subsequent bone involvement. In particular,
48% of patients who experienced distant disease presented with
bone metastasis. A high incidence of subsequent relapse in bone
was also found in the retrospective analyses of pattern of
recurrence in patients included in the adjuvant studies of
International Breast Cancer Study Group trial between 1978
and 1993 [24]. The authors reported a 10-year cumulative
incidence of 36.7% with regard to skeletal involvement at any
time. The analysis of pattern of distant relapse in patients who
experienced LRR could suggest the implementation of strategy
to reduce the rate of bone involvement in patients with LRR
with bisphosphonates, which might reduce the relapse of
growth factors from microfoci of bone destruction, thereby
reducing bone absorption and decreasing stimuli of
micrometastatic breast cancer [25, 26].
The finding that patients with LRR remain at substantial risk
of relapse, was observed despite hormonal and/or
chemotherapy program (Table 1), which might have interfered
with the outcome. The benefit of hormonal therapy after LRR
was reported. The trial by Waeber et al. [27], compared
tamoxifen with observation in 167 patients who underwent radical
A B
Figure 2. Cumulative incidence of distant event after first locoregional recurrence, by type of first recurrence, in patients with time to first recurrence <2
years (A) and >2 years (B).
A B
Figure 3. Progression-free survival (A) and overall survival (B) after first LRR (locoregional recurrence), by subtypes evaluated at LRR. Note: If any
biological variable was missing at locoregional recurrence, the value at primary breast cancer was used. The value of Ki-67 expression was missing at
locoregional recurrence in 12 luminal A, 48 luminal B, 9 HER2-positive and 15 triple-negative breast cancer subtypes. The HER2 status was missing at
locoregional recurrence in one HER2-positive and two triple-negative breast cancer subtypes.
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surgery and radiotherapy for post mastectomy LRR. After a median
follow up of 11 years, tamoxifen therapy significantly improves PFS.
This beneficial effect does not translate into a detectable OS
advantage. On the other hand, the utility of chemotherapy for
women who experience an LRR remains an open question. An
international collaborative trial BIG 1-02/IBCSG 27-02/NSABP B-37
is currently being conducted to determine the effectiveness of
cytotoxic therapy for these patients.
In conclusion, we demonstrated that LRR correlate with high
risk of subsequent events and death in particular within the
triple-negative subtype. New chemotherapy regimens or
combinations should be explored in this cohort of patients with
poor outcome. Moreover, the variation of biologic parameters
between primary tumor and LRR and the related clinical and
therapeutic implications, support a histopathologic
reevaluation of the disease at the time of LRR.
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